AquinoxªÑ»ù ¨â¤é¨g‘C¤Q¿
·sÃĬãµo§Q¦h
¡i©ú³ø±M°T¡j¤@¦W¤ÀªR®v«ü¨äªvÀø»H¯Öµh¯g¤ÎÀã¯lÃĪ«±¥@¾÷·|¸û¹w´Á°ª¤§«á¡AAquinox Pharmaceuticals Inc.(¥N¸¹AQXP)ªÑ»ù«æ¤É¹O5¿¡C¦b©P¤@¥«¤¤¡AAquinoxªÑ»ù´¿¤@«×¨£55.75¬ü¤¸ªº·í¤é°ªÂI¡A¨ä«á¥H18.88¬ü¤¸¦¬¥«¡A¤É8.46¬ü¤¸¡A©Î81.19%¡CY¹ï¤ñ¤W©P¥|ªº1.79¬ü¤¸¦¬¥«»ù¡A«hº¦ªñ¤Q¿¡C
Aquinox¬°©P¤@¯Ç«ü¤¤³Ì¤j¤W¤ÉªÑ¡CAquinox©ó¤W©P¥|±ßªí¥Ü¡A¦b¤@Ó쥻«Å§i¥¢±Ñªº»H¯Öµh¯g¬ã¨s¤¤µo²{¦³±æªº¼Æ¾Ú¡F¦P®É¤Sªí¥Ü¡A¥t¤@Ó¦³ÃöÀã¯l¬ã¨s±o¥X¦¨ªGªº¤é´Á¡A·|¸û¹w´Á¬°¦¡CCowen & Co.¤ÀªR®vRitu BaralºÙ¡A¤Wz¦W¬°AQX-1125ªºÃĪ«²{®É¦bªvÀø»H¯Öµh¤W§Æ±æ¤w¸û«e¬°¤j¡A¥B¥i¯à·|¦bªvÀøÀã¯l¤W¦³©Ò§@¬°¡C
AquimoxºÙ¡A¦b¦Ò¹î¤Wz«Å§i¥¢±Ñªº¬ã¨s³ø§iÅã¥ÜÃĪ«¹ï»H¯Öµh¦³¤@©w®Ä¤O«á¡A¨M©w±NÄ~Äò¬ãµoAQX-1125¡C¦¹®a¥H·ÅôµØ¬°°ò¦aªº¤½¥q¤Sªí¥Ü¡A·|»P¬ü°ê©M¼Ú¬wªº³WºÞ·í§½°Ó°Q¡A¦³Ãö³]p³Ì²×¶¥Á{§É¹êÅ窺°ÝÃD¡C
¹ï¨R°òª÷Baker Brothers Advisors LP©P¤@¦b¤@¥÷§e¥æ¬ü°êÃÒ¥æ·|¤å¥ó¤¤©ÜÅS¡A«ù¦³Aquinox39.8%ªÑÅv¡C¦¹¥~¡A»sÃĤ½¥q½÷·ç(Pfizer Inc.)¤Î²ø¦Ú(Johnson & Johnson)³£¦³§ë¸ê©óAquinox¡C
Aquinox¦P®É¹w´Á¡A·|¦b¤µ¦~¦~©³±o¥X¦³Ãö¦¹ºØÃĪ«ªvÀøÀã¯lªº¤¤´Á¬ã¨sµ²ªG¡C¤µ¦~5¤ëªì¡A¯A¤Î¬ù50¦W±wªÌªº¤@¶µ¬ÛÃö¬ã¨s¤w§i§¹¦¨¡C¦b¤@¥÷¤µ®L¤½¥¬ªº¬ã¨s³ø§i¤¤¡A¦¹ÃÄ¥¼¯à¹ïºC©ÊªÍªý¶ë¯f¤H²£¥ÍÀø®Ä¡C